Abstract
To clarify changes in estrogen receptor (ER) α and ERβ during endometrial tumorigenesis, 48 endometrial carcinomas (endometrioid type), as well as 40 samples of normal endometrial tissue, were investigated using a combination of reverse‐transcription and polymerase chain reaction with Southern blot hybridization and western blot assays, and the results were compared with findings for progesterone receptor (PR) and pS2 mRNA status. In addition, 166 carcinomas were also examined for immunohistochemistry, along with 171 normal specimens. Relative amounts of ERα at both mRNA and protein levels were significantly greater than those for ERβ in normal and malignant endometrial lesions. ERα mRNA showed a stepwise decrease from normal or grade (G) 1 through to G3 tumor lesions, in line with changes in the protein levels, in contrast to ERβ mRNA or protein expression, which did not alter, suggesting a shift in the ratio of the two ER subtypes during endometrial tumorigenesis. PR mRNA expression was significantly correlated with ERα, but not ERβ mRNA status. Although significantly higher expression of pS2 mRNA or protein was observed in carcinomas than in the normal cases, there was no apparent association with the ER status. The findings suggest that alteration in estrogen signaling pathways may occur during endometrial tumorigenesis, and provide evidence that ERα expression may play an important role in the regulation of PR, but not pS2 expression in normal and malignant endometrium.
Keywords: ERα, ERβ PR, pS2 endometrial carcinoma
Full Text
The Full Text of this article is available as a PDF (1.8 MB).
REFERENCES
- 1. ) Deligdisch , L. and Cohen , C. J.Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia . Cancer , 56 , 1452 – 1455 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Evans , R. M.The steroid and thyroid hormone receptor superfamily . Science , 240 , 889 – 895 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. ) Kumar , V. , Green , S. , Stack , G. , Berry , M. , Jin , J. R. and Chambon , P.Functional domains of the human estrogen receptor . Cell , 51 , 941 – 951 ( 1987. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Daffada , A. A. I. , Johnston , S. R. D. , Smith , I. E. , Detre , S. , King , N. and Dowsett , M.Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer . Cancer Res. , 55 , 288 – 293 ( 1995. ). [PubMed] [Google Scholar]
- 5. ) Fuqua , S. A. W. , Fitzgerald , S. D. , Chamness , G. C. , Tandon , A. K. , McDonnell , D. P. , Nawaz , Z. , O'Malley , B. W. and McGuire , W. L.Variant human breast tumor estrogen receptor with constitutive transcriptional activity . Cancer Res. , 51 , 105 – 109 ( 1991. ). [PubMed] [Google Scholar]
- 6. ) Mosselman , S. , Polman , J. and Dijkema , R.ERβ: identification and characterization of a novel human estrogen receptor . FEBS Lett. , 392 , 49 – 53 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 7. ) Leygue , E. , Dotzlaw , H. , Watson , P. H. and Murphy , L. C.Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis . Cancer Res. , 58 , 3197 – 3201 ( 1998. ). [PubMed] [Google Scholar]
- 8. ) Brandenberger , A. W. , Tee , M. K. and Jaffe , R. B.Estrogen receptor α (ER‐α) and β (ER‐β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down‐regulation of ER‐β in neoplastic tissues . J. Clin. Endocrinol. Metab. , 83 , 1025 – 1028 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Chan , C. M. W. and Dowsett , M.A novel estrogen receptor variant mRNA lacking exons 4 to 6 in breast carcinoma . J. Steroid Biochem. Mol. Biol. , 62 , 419 – 430 ( 1997. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Leygue , E. R. , Watson , P. H. and Murphy , L. C.Estrogen receptor variants in normal human mammary tissue . J. Natl. Cancer Inst. , 88 , 284 – 290 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 11. ) Carr , M. , May , F. E. B. , Lennard , T. W. J. and Westley , B. R.Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription‐polymerase chain reaction . Br. J. Cancer , 72 , 1427 – 1434 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. ) Valdusic , E. A. , Hornby , A. E. , Guerra‐Vladusic , F. K. and Lupu , R.Expression of estrogen receptor β messenger RNA variant in breast cancer . Cancer Res. , 58 , 210 – 214 ( 1998. ). [PubMed] [Google Scholar]
- 13. ) Pujol , P. , Rey , J.‐M. , Nirde , P. , Roger , P. , Gastaldi , M. , Laffargue , F. , Rochefort , H. and Maudelonde , T.Differential expression of estrogen receptor‐α and ‐β messenger RNAs as a potential marker of ovarian carcinogenesis . Cancer Res. , 58 , 5367 – 5373 ( 1998. ). [PubMed] [Google Scholar]
- 14. ) Saegusa , M. and Okayasu , I.Up‐regulation of CD44 variant exon expression in endometrial carcinomas: analysis of mRNA and protein isoforms, and relation to clinicopathological factors . Jpn. J. Cancer Res. , 89 , 291 – 298 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. ) Dotzlaw , H. , Leygue , E. , Watson , P. H. and Murphy , L. C.Estrogen receptor‐β messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins . Cancer Res. , 59 , 529 – 532 ( 1999. ). [PubMed] [Google Scholar]
- 16. ) Saegusa , M. , Hashimura , M. and Okayasu , I.CD44 expression in normal, hyperplastic, and malignant endometrium . J. Pathol. , 184 , 297 – 306 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 17. ) Sinicrope , F. A. , Ruan , S. B. , Cleary , K. B. , Stephens , L. C. , Lee , J. J. and Levin , B.Bcl‐2 and p53 oncoprotein expression during colorectal tumorigenesis . Cancer Res. , 55 , 237 – 241 ( 1995. ). [PubMed] [Google Scholar]
- 18. ) Kuiper , G. G. J. M. and Gustafsson , J.‐A.The novel estrogen receptor‐β subtype: potential role in the cell‐ and promoter‐specific actions of estrogens and anti‐estrogens . FEBS Lett. , 410 , 87 – 90 ( 1997. ). [DOI] [PubMed] [Google Scholar]
- 19. ) Brandenberger , A. W. , Lebovic , D. I. , Tee , M. K. , Ryan , I. P. , Tseng , J. F. , Jaffe , R. B. and Taylor , R. N.Oestrogen receptor (ER)‐α and ER‐β isoforms in normal endometrial and endometriosis‐derived stromal cells . Mol. Hum. Reprod. , 5 , 651 – 655 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 20. ) Castles , C. G. , Fuqua , S. A. W. , Klotz , D. M. and Hill , S. M.Expression of a constitutively active estrogen receptor variant in the estrogen receptor‐negative BT‐20 human breast cancer cell line . Cancer Res. , 53 , 5934 – 5939 ( 1993. ). [PubMed] [Google Scholar]
- 21. ) Rea , D. and Parker , M. G.Effects of an exon 5 variant of the estrogen receptor in MCF‐7 breast cancer cells . Cancer Res. , 56 , 1556 – 1563 ( 1996. ). [PubMed] [Google Scholar]
- 22. ) Desai , A. J. , Luqmani , Y. A. , Walters , J. E. , Coope , R. C. , Dagg , B. , Gomm , J. J. , Pace , P. E. , Rees , C. N. , Thirunavukkarasu , V. , Shousha , S. , Groome , N. P. , Coombes , R. and Ali , S.Presence of exon 5‐deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance . Br. J. Cancer , 75 , 1173 – 1184 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. ) Ohlsson , H. , Lykkesfeldt , A. E. , Madsen , M. W. and Briand , P.The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT‐3522S1 . Cancer Res. , 58 , 4264 – 4268 ( 1998. ). [PubMed] [Google Scholar]
- 24. ) Langdon , S. P. , Gabra , H. , Bartlett , J. M. S. , Rabiaz , G. J. , Hawkins , R. A. , Tesdale , A. L. , Ritchie , A. A. , Miller , W. R. and Smyth , J. F.Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen . Clin. Cancer Res. , 4 , 2245 – 2251 ( 1998. ). [PubMed] [Google Scholar]
- 25. ) Langdon , S. P. , Hirst , G. L. , Miller , E. P. , Hawkins , R. A. , Tesdale , A. L. , Smyth , J. F. and Miller , W. R.The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines . J. Steroid Biochem. Mol. Biol. , 50 , 131 – 135 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 26. ) Saegusa , M. and Okayasu , I.Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis . Cancer , 83 , 111 – 121 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 27. ) Creasman , W. T. , McCarty , K. S. , Sr. , Barton , T. K. and McCarty , K. S. , Jr.Clinical correlates of estrogen‐ and progesterone‐binding proteins in human endometrial carcinomas . Obstet. Gynecol. , 55 , 363 – 370 ( 1980. ). [DOI] [PubMed] [Google Scholar]
- 28. ) Ehrlich , C. E. , Young , P. C. M. and Cleary , R. E.Cytoplasmic progesterone receptors in normal, hyperplastic, and carcinomatous endometrium: therapeutic implications . Am. J. Obstet. Gynecol. , 141 , 539 – 546 ( 1981. ). [DOI] [PubMed] [Google Scholar]
- 29. ) Masiakowski , P. , Breathnach , R. , Bloch , J. , Gannon , F. , Krust , A. and Chambon , P.Cloning of cDNA sequences of hormone‐regulated genes from the MCF‐7 human breast cancer cell line . Nucleic Acids Res. , 10 , 7895 – 7903 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. ) Brown , A. M. , Jeltsch , J. M. , Roberts , M. and Chambon , P.Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF‐7 . Proc. Natl. Acad. Sci. USA , 81 , 6344 – 6348 ( 1984. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. ) Nunez , A. M. , Berry , M. , Imler , J. and Chambon , P.The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c‐H‐ras oncoprotein and the c‐jun protein . EMBO J. , 8 , 823 – 829 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. ) Koshiyama , M. , Yoshida , M. , Konishi , M. , Takemura , M. , Yura , Y. , Matsushita , K. , Hayashi , M. and Tauchi , K.Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathological features and sex steroid receptor status . Int. J. Cancer , 74 , 237 – 244 ( 1997. ). [DOI] [PubMed] [Google Scholar]
- 33. ) Thompson , A. M. , Elton , R. A. , Hawkins , R. A. , Chetty , U. and Steel , C. M.PS2 mRNA expression adds prognostic information to node status for 6‐year survival in breast cancer . Br. J. Cancer , 77 , 492 – 496 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. ) Singh , S. , Poulson , R. , Hanby , A. M. , Rogers , L. A. , Wright , N. A. , Sheppard , M. C. and Langman , M. J. S.Expression of oestrogen receptor and oestrogen‐inducible genes pS2 and ERD5 in large bowel mucosa and cancer . J. Pathol. , 184 , 153 – 160 ( 1998. ). [DOI] [PubMed] [Google Scholar]